GlassScriptPhysician profile
Nancy A Boelter
NPI 1629015177
$2,945.50
in general payments reported to CMS, 2019-2025
26 companies · $476 in 2025
The $476 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $748 · 2020: $228 · 2021: $481 · 2022: $39.85 · 2023: $391 · 2024: $582 · 2025: $476.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,449.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,448.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $438.58 | 2021-2025 | Ubrelvy, Liletta, Qulipta |
| Pfizer INC. | $353.37 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $340.75 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Amgen INC. | $276.71 | 2019-2025 | Repatha, Otezla, Repatha |
| Janssen Pharmaceuticals, INC | $273.77 | 2019-2023 | Xarelto |
| Novo Nordisk INC | $226.13 | 2019-2025 | Ozempic, Rybelsus |
| Boehringer Ingelheim Pharmaceuticals, INC. | $211.84 | 2019-2025 | Jardiance, Tradjenta, Synjardy |
| Lilly USA, LLC | $155.08 | 2019-2021 | |
| Phathom Pharmaceuticals, INC. | $105.05 | 2024-2025 | Voquezna |
| Allergan, INC. | $70.93 | 2019-2020 | |
| Biohaven Pharmaceuticals, INC. | $59.86 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $54.87 | 2019-2023 | Trulance, Xifaxan |
| Takeda Pharmaceuticals U.S.A., INC. | $53.18 | 2021 | |
| Abbott Laboratories | $43.81 | 2023-2025 | Freestyle Libre 3 |
| Novartis Pharmaceuticals Corporation | $43.15 | 2019-2023 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $37.95 | 2019-2025 | Shingrix |
| Merck Sharp & Dohme LLC | $37.01 | 2023-2024 | Vaxelis, Gardasil 9, Capvaxive |
| Sanofi Pasteur INC. | $27.33 | 2019-2020 | |
| Jazz Pharmaceuticals INC. | $22.78 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $20.61 | 2022 | |
| Amarin Pharma, INC. | $20.16 | 2021 | |
| Xeris Pharmaceuticals, INC. | $18.50 | 2024 | Gvoke Hypopen |
| Supernus Pharmaceuticals, INC. | $15.01 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $13.99 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $13.31 | 2023 | |
| Genentech USA, INC. | $11.77 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nancy Boelter listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.